Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
08/08/2023* 16:30 EST Earnings Call Q2 2023 -- -- --
11/04/2022* -- Results Q3 2022 -- -0.25 --
08/08/2022 -- Results Q2 2022 -0.23 -0.21 -7.81%
08/08/2022 16:30 EST Earnings Call Q2 2022 -- -- --
05/09/2022 -- Results Q1 2022 -0.20 -0.17 -15.39%
02/24/2022 -- Results Q4 2021 -0.17 -0.16 -7.94%
11/04/2021 -- Results Q3 2021 -0.14 -0.14 0.00%
08/05/2021 -- Results Q2 2021 -0.13 -0.14 7.14%
*Estimated Date/Time

Earnings

Next Report Date 11/04/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 08/08/2022
Beat/Miss Upgrade
Return Since -47.79%
Last FQE 06/30/2022
Next FQE 09/30/2022

Profile

Edit
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.
URL https://www.vaxart.com
Investor Relations URL https://investors.vaxart.com/
HQ State/Province California
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Nov. 04, 2022 (est.)
Last Earnings Release Aug. 08, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date Nov. 09, 2012

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date Nov. 09, 2012
Yield (TTM) 0%
Forward Yield --
Payout Ratio --
Cash Payout Ratio --
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
-13.39%
-36.60%
-53.96%
-69.82%
-81.36%
1.53K%
9.81%
-64.27%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-19.50%
-26.80%
3.27%
-40.49%
-3.15%
-17.50%
168.2%
-43.62%
-63.33%
41.48%
-84.98%
-1.59%
48.39%
-89.18%
2.70K%
28.30%
-86.44%
-14.78%
-47.58%
48.46%
17.10%
-95.00%
-57.48%
77.60%
-58.56%
-29.98%
-3.92%
188.7%
-44.30%
-11.54%
-50.69%
-53.58%
-32.03%
As of October 04, 2022.

Profile

Edit
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.
URL https://www.vaxart.com
Investor Relations URL https://investors.vaxart.com/
HQ State/Province California
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Nov. 04, 2022 (est.)
Last Earnings Release Aug. 08, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date Nov. 09, 2012

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

No data available
Symbol Dollars Invested % Weight
     
     
     
     
     
     
     
     
     
     

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter VXRT Tweets